翰森制药获批HS-10561胶囊临床试验

财中社
25 Feb

  2月25日,翰森制药(03692)发布公告,宣布其与广州麓鹏制药有限公司合作的1类小分子布鲁顿酪氨酸激酶抑制剂HS-10561胶囊,已获得中国国家药品监督管理局签发的药物临床试验批准通知书。该临床试验计划用于慢性自发性荨麻疹的治疗,标志着公司在研发领域的重要进展。

  此次获批的HS-10561胶囊是公司在创新药物开发方面的又一里程碑,显示了公司在生物制药领域的实力与潜力。此公告对于投资者和市场而言,均具有积极的信号,可能会进一步提升公司的市场价值和股东信心。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10